Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Advanced co-culture 3D breast cancer model for investigation of fibrosis induced by external stimuli: optimization study.

Tytuł:
Advanced co-culture 3D breast cancer model for investigation of fibrosis induced by external stimuli: optimization study.
Autorzy:
Yakavets I; UMR7039 CRAN, Institut de Cancérologie de Lorraine, CNRS, Université de Lorraine, 6 Avenue de Bourgogne, 54519, Vandoeuvre-lès-Nancy, France.
Francois A; UMR7039 CRAN, Institut de Cancérologie de Lorraine, CNRS, Université de Lorraine, 6 Avenue de Bourgogne, 54519, Vandoeuvre-lès-Nancy, France.
Benoit A; UMR7039 CRAN, Institut de Cancérologie de Lorraine, CNRS, Université de Lorraine, 6 Avenue de Bourgogne, 54519, Vandoeuvre-lès-Nancy, France.
Merlin JL; UMR7039 CRAN, Institut de Cancérologie de Lorraine, CNRS, Université de Lorraine, 6 Avenue de Bourgogne, 54519, Vandoeuvre-lès-Nancy, France.
Bezdetnaya L; UMR7039 CRAN, Institut de Cancérologie de Lorraine, CNRS, Université de Lorraine, 6 Avenue de Bourgogne, 54519, Vandoeuvre-lès-Nancy, France. .
Vogin G; UMR7039 CRAN, Institut de Cancérologie de Lorraine, CNRS, Université de Lorraine, 6 Avenue de Bourgogne, 54519, Vandoeuvre-lès-Nancy, France.; UMR 7365 CNRS-UL, IMoPA, Vandœuvre-lès-Nancy, France.; Centre François Baclesse, Centre National de Radiothérapie du Grand-Duché du Luxembourg, Esch Sur Alzette, Luxembourg.
Źródło:
Scientific reports [Sci Rep] 2020 Dec 04; Vol. 10 (1), pp. 21273. Date of Electronic Publication: 2020 Dec 04.
Typ publikacji:
Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:
Breast Neoplasms*
Coculture Techniques*
Models, Biological*
Humans ; MCF-7 Cells ; Spheroids, Cellular ; Tumor Cells, Cultured
References:
Nat Rev Dis Primers. 2019 Sep 23;5(1):66. (PMID: 31548545)
Front Pharmacol. 2018 Jan 23;9:6. (PMID: 29410625)
Support Care Cancer. 2005 Oct;13(10):775-80. (PMID: 16041503)
J Cancer Res Clin Oncol. 2015 Nov;141(11):1985-94. (PMID: 25910988)
Genes Dev. 2016 May 1;30(9):1002-19. (PMID: 27151975)
Mol Cell Pharmacol. 2009;1(1):44-56. (PMID: 20336170)
Sci Rep. 2020 Feb 3;10(1):1653. (PMID: 32015396)
PLoS One. 2019 Mar 21;14(3):e0210263. (PMID: 30897102)
Int J Nanomedicine. 2017 Oct 31;12:7993-8007. (PMID: 29184400)
Exp Hematol. 2007 Apr;35(4 Suppl 1):96-104. (PMID: 17379094)
Oncogene. 2019 Apr;38(17):3261-3273. (PMID: 30631150)
J Biomol Screen. 2006 Dec;11(8):922-32. (PMID: 16973921)
Eur J Pharm Biopharm. 2020 Sep;154:33-42. (PMID: 32634570)
Biochim Biophys Acta. 2013 Jul;1832(7):1070-8. (PMID: 23123598)
Med Dosim. 2016 Autumn;41(3):253-7. (PMID: 27545009)
Int Wound J. 2008 Mar;5(1):40-4. (PMID: 18081782)
Mol Carcinog. 2020 Jul;59(7):754-765. (PMID: 32363633)
Biotechnol J. 2008 Oct;3(9-10):1172-84. (PMID: 18566957)
Acta Oncol. 1995;34(3):413-7. (PMID: 7779433)
Radiat Res. 2018 Mar;189(3):326-336. (PMID: 29351058)
Nat Rev Cancer. 2006 May;6(5):392-401. (PMID: 16572188)
Cancers (Basel). 2019 Sep 13;11(9):. (PMID: 31540319)
J Clin Med. 2019 Oct 15;8(10):. (PMID: 31618880)
Science. 2002 May 10;296(5570):1046-9. (PMID: 12004111)
Recent Results Cancer Res. 1976;(57):33-41. (PMID: 1013510)
Cell Adh Migr. 2012 May-Jun;6(3):249-60. (PMID: 22568982)
Nat Protoc. 2009;4(3):309-24. (PMID: 19214182)
Cell Res. 2009 Feb;19(2):156-72. (PMID: 19153598)
J Clin Invest. 2007 Mar;117(3):524-9. (PMID: 17332879)
Int J Dev Biol. 2004;48(5-6):509-17. (PMID: 15349825)
Acta Biomater. 2017 Feb;49:152-166. (PMID: 27916739)
Growth Factors. 2011 Oct;29(5):196-202. (PMID: 21740331)
Cell Commun Signal. 2019 May 17;17(1):47. (PMID: 31101063)
Sci Rep. 2016 Jul 01;6:28951. (PMID: 27364600)
Front Oncol. 2019 Mar 19;9:153. (PMID: 30941305)
Radiother Oncol. 2010 Oct;97(1):149-61. (PMID: 20888056)
Br J Cancer. 2004 Feb 23;90(4):822-32. (PMID: 14970860)
Oncol Lett. 2018 Mar;15(3):3008-3016. (PMID: 29435031)
J Pathol. 2003 Jul;200(4):500-3. (PMID: 12845617)
J Mammary Gland Biol Neoplasia. 2016 Dec;21(3-4):89-98. (PMID: 27518775)
Exp Cell Res. 2001 May 15;266(1):74-86. (PMID: 11339826)
Nat Rev Cancer. 2006 Sep;6(9):702-13. (PMID: 16929324)
J Histochem Cytochem. 2011 Dec;59(12):1087-100. (PMID: 22034518)
Entry Date(s):
Date Created: 20201205 Date Completed: 20210329 Latest Revision: 20210329
Update Code:
20240104
PubMed Central ID:
PMC7718236
DOI:
10.1038/s41598-020-78087-7
PMID:
33277538
Czasopismo naukowe
Radiation-induced fibrosis (RIF) is the main late radiation toxicity in breast cancer patients. Most of the current 3D in vitro breast cancer models are composed by cancer cells only and are unable to reproduce the complex cellular homeostasis within the tumor microenvironment to study RIF mechanisms. In order to account complex cellular interactions within the tumor microenvironment, an advanced 3D spheroid model, consisting of the luminal breast cancer MCF-7 cells and MRC-5 fibroblasts, was developed. The spheroids were generated using the liquid overlay technique in culture media into 96-well plates previously coated with 1% agarose (m/v, in water). In total, 21 experimental setups were tested during the optimization of the model. The generated spheroids were characterized using fluorescence imaging, immunohistology and immunohistochemistry. The expression of ECM components was confirmed in co-culture spheroids. Using α-SMA staining, we confirmed the differentiation of healthy fibroblasts into myofibroblasts upon the co-culturing with cancer cells. The induction of fibrosis was studied in spheroids treated 24 h with 10 ng/mL TGF-β and/or 2 Gy irradiation. Overall, the developed advanced 3D stroma-rich in vitro model of breast cancer provides a possibility to study fibrosis mechanisms taking into account 3D arrangement of the complex tumor microenvironment.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies